Predictors of state-of-the-art management of early breast cancer in Switzerland by Ess, S. et al.
Annals of Oncology 22: 618–624, 2011
doi:10.1093/annonc/mdq404
Published online 12 August 2010
original article
Predictors of state-of-the-art management of early
breast cancer in Switzerland
S. Ess1*, M. Joerger1,2, H. Frick3, N. Probst-Hensch4,5, G. Vlastos6, C. Rageth7, U. Lu¨tolf8,
A. Savidan1 & B. Thu¨rlimann9
1Cancer Registry St Gallen–Appenzell, Cancer League St. Gallen-Appenzell, St Gallen; 2Oncology Department, Cantonal Hospital St Gallen, St Gallen; 3Cancer Registry
Grison–Glarus and Department of Pathology, Cantonal Hospital Graubu¨nden, Chur; 4Cancer Registry Zurich (former); 5Swiss Tropical and Public Health Institute,
University of Basel, Basel; 6Senology Unit, Geneva University Hospitals, Geneva; 7Brust-Zentrum Seefeld, Zurich; 8Department of Radio-Oncology, Zurich University
Hospital, Zurich; 9Breast Center, Cantonal Hospital St Gallen, St Gallen, Switzerland
Received 2 April 2010; revised 11 June 2010; accepted 14 June 2010
Background: The aim of this study was to investigate predictors of state-of-the-art management of early breast
cancer in Switzerland.
Patients and methods: The study included 3499 women aged 25–79 years diagnosed with invasive breast cancer
stages I–IIIA in 2003–2005. Patients were identified through population-based cancer registries and treated in all kinds
of settings. Concordance with national and international recommendations was assessed for 10 items covering
surgery, radiotherapy, systemic adjuvant therapy and histopathology reporting. We used multivariate logistic
regression to identify independent predictors of high (10 points) and low (£7 points) concordance.
Results: In one-third of the patients, management met guidelines in all items, whereas in about one-fifth, three
or more items did not comply. Treatment by a surgeon with caseload in the upper tercile and team involved in
clinical research were independent predictors of a high score, whereas treatment by a surgeon with a caseload in the
lower tercile was associated with a low score. Socioeconomic characteristics such as income and education
were not independent predictors, but patient’s place of residence and age independently predicted management
according to recommendations.
Conclusion: Specialization and involvement in clinical research seem to be key elements for enhancing the quality of
early breast cancer management at population level.
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introduction
Two recently published studies have described geographical
disparities in breast cancer mortality [1] and 5-year relative
survival rates in Switzerland after controlling for prognostic
factors like tumor size and nodal status [2]. These differences
suggest that factors other than stage at diagnosis might
influence clinical outcome. In fact, geographical heterogeneity
in the process of care (early detection and treatment) has
been reported recently [3]. It remains unclear whether these
regional disparities are associated with differences in access to
specialized breast cancer care.
The Swiss health care system is characterized by universal
health care insurance coverage, readily available access together
with liberalism in and fragmentation of care provision.
Although treatment of breast cancer in specialized units has
been shown to result in better outcomes [4–7], there is still
much debate whether specialization in breast cancer care is
needed and whether differences that matter to the patient
exist in Switzerland.
Many studies have evaluated the relation between the
characteristics of the source of care and the outcomes of
patients with breast cancer in developed countries.
Characteristics of both patients and health care providers [8]
have been related to these variations. Hospital and physician
volume [9], specialization [10, 11], participation in research
[9], multidisciplinary teams [12] and treatment in accordance
to guidelines [13] have been found to affect both the way
patients are cared for and the outcomes. Variations in
treatment include type of breast and axillary surgery, and use
of chemotherapy, hormone therapy and radiation therapy.
Switzerland devotes 10.8% of its gross domestic product for
health and its health care system is one of the most expensive
among developed countries [14, 15]. Little is known, however,
on how the system functions and patients cannot easily
recognize where specialized high-quality care is provided. The
aim of the present study was, therefore, to analyze whether
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differences in the implementation of state-of-the-art
management exist and find predictors for adequate and poor
management of early breast in Switzerland.
methods
A 10-item score of state-of-the-art management was defined based on
national [16–20] and international [21–27] guideline items available at
the time diagnosis was made and treatments were provided. The score
included five items for surgical management, one item for histopathology
reporting, and four items for adjuvant radiotherapy and systemic
treatment. One point was given for complying with each respective item or
when the recommendation was not requested by the guideline for the
individual case. Details on items of the score are given in Table 1.
study population
Patients were identified from seven population-based cancer registries and
were included in the Swiss Patterns of Care in Breast Cancer Study
(Swiss PoC), which analyzed breast cancer cases diagnosed between 1
January 2003 and 31 December 2005 [28]. For this analysis, we included
3499 women with early breast cancer (stages I–IIIA according to [29]).
We restricted our cohort to patients aged 25–79 years diagnosed with
epithelial malignancies (International Classification of Diseases for
Oncology-3 codes M8010-M8579) and operated with curative intention.
We excluded women 80 years and older as this population is heterogeneous
with respect to factors such as number of comorbidities and life expectancy,
and the lack of adherence to recommendations may be related to such
factors. Only one tumor per patient was considered. The index tumor
was defined as being the one with higher stage according to Greene et al.
[29] in case of synchronous bilateral tumor (e.g. diagnosis made within
30 days) or the first diagnosed in the period of interest in case of
metachronous independent bilateral breast cancer.
The participating cancer registries cover roughly 3.5 Mio inhabitants
(47% of the Swiss population) and are regular contributors to ‘Cancer in
5 Continents’ [30, 31]. Routine indicators of data completeness and quality
of the participating registries are good: 1%–3% of case patients are
registered on the basis of death certificates only. The proportion of
histological verification is >90% [30, 31]. Details of the methodology are
provided elsewhere [28]. In brief, based on the requirements of the
European Society of Mastology (EUSOMA) Audit system on Quality of
Breast Cancer Treatment criteria [32], a database was designed and a special
software application for data entry distributed to the registries to minimize
data entry errors. Items included detailed information on patient and
tumor characteristics, diagnosis circumstances and treatments planed and
delivered as part of the first therapeutic concept. Therapies planned and
delivered because of recurrence or disease progression were not considered.
Experienced staff of the registries was centrally instructed and trained,
subsequently data items abstracted from pathology reports and medical
charts. To complete information on therapies delivered in the outpatient
setting or for pieces of information lacking in the hospital charts,
questionnaires were sent to family doctors or treating gynecologists. The
use of questionnaires complementary to chart review allowed high
completeness of information concerning adjuvant therapies (>95%).
Registries could choose between collecting information on all registered and
eligible cases or on a random sample of at least 500 cases. Five registries
(Geneva, Valais, Ticino, St Gallen–Appenzell and Grisons–Glarus)
collected information on all registered cases diagnosed in their respective
catchment areas in the study period, whereas two registries (Basel city
and countryside and Zurich) collected information on a sample of 505 cases
selected at random. Tests of representativeness of the samples of those two
registries regarding age distribution, breast cancer laterality, morphology
Table 1. Items used to construct the state-of-the-art breast cancer
management score and adherence to items
No. of patients (%) References
1 point 0 point
Surgical items
Pretreatment diagnostic by FNA
or CNB
2687 (76) 812 (24) [17, 23]
‡1-mm tumor-free margin after
final surgerya
3199 (91) 300 (9) [16]
Removal of ‡10 LN when
undergoing AND
1657 (47) 649 (18) [18]
Not requestedb 1193 (34) –
Sentinel node as definitive
procedure in pathologically
confirmed N0 disease
1119 (34) [18, 22]
Not requestedb,c 1158 (34) 1160 (33)
One breast surgeryd 2674 (76) 825 (24) [23, 26, 27]
Nonsurgical items
Reporting of hormone receptor
immunoreactivity (in % positive
cells), tumor size and grading
3426 (96) 73 (2) [17, 24]
Nonapplicablee 51 (1) –
Adjuvant radiotherapy following
BCS
2348 (67) 151 (4)
Not requestedf 964 (29) – [19, 25]
Adjuvant radiotherapy following
mastectomy if requestedg
236 (7) 136 (4)
Not requestedh 3217 (89) – [19, 25]
Endocrine therapy prescribed if
requestedi
2720 (78) 170 (5) [20, 22]
Nonapplicablej 609 (17) –
Chemotherapy prescribed when
requestedk
1455 (43) 324 (9)
Nonapplicablel 1720 (49) – [20, 22]
Percentages may not sum up to 100 because of rounding.
aFor both invasive and in situ breast cancer.
bNot requested in patients receiving neoadjuvant systemic chemotherapy or
if sentinel node biopsy in node-negative disease was carried out.
cNot requested in patients with positive lymph nodes.
dTo achieve negative margins as well as axillary procedure.
eNot requested if not mentioned in patients with neoadjuvant
chemotherapy.
fNot requested if mastectomy was carried out or the patient refused
radiotherapy.
gRequested for patients with locally advanced disease or positive margins.
hNot requested if BCS was carried out or mastectomy carried out with
characteristics other than those specified in the footnote above (g) or if the
patient refused radiotherapy.
iRequested if endocrine-sensitive disease except minimal risk according to
Goldhirsch et al. [22].
jNot requested if minimal risk or endocrine-unresponsive disease.
kChemotherapy requested for endocrine-unresponsive disease and for
endocrine-responsive disease if nodal involvement and locally advanced
disease (facultative for high histological grade, vessel invasion or HER2
overexpression).
lNonapplicable if chemotherapy not prescribed and not requested by guideline.
AND, (conventional) axillary node dissection; BCS, breast-conserving
surgery; CNB, core needle biopsy; FNA, fine needle aspiration; LN, lymph
nodes.
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and stage showed similar values as those of registries that had collected
the totality of cases. Breast cancer staging used the 6th edition of the
American Joint Committee on Cancer staging criteria [29]. The study
was submitted to and accepted by the Cantonal Ethics Committee in
St Gallen, where the study center is located.
Socioeconomic covariates studied in the present analysis included age,
nationality (as proxy for migrant), canton of residence, urban/suburban
versus rural residence and affluence categorized to the highest quartile of
median income in the small residence area in the Swiss PoC population.
The level of education attained (tertiary education versus other) was
derived from the type of occupation of the patient.
Provider characteristics included setting of the initial therapy (surgery in
a public versus private hospital), patient discussion at a pre- and
postoperative or only postoperative multidisciplinary tumor conference
(MDTC) (including at least a surgeon, pathologist, radio-oncologist and
medical oncologist), involvement of the team in clinical research and
estimated number of breast cancer patients per surgeon and year. This
number was calculated from the number of cases recorded by the registry
and weighted for sampling probability. For institutions in the public
sector, it was assumed that three surgeons per institution operated on breast
cancer patients. In private hospitals, each surgeon received a distinct
anonymous code. All information on provider characteristics was lacking
for the region Ticino and caseload could not be determined for patients
treated in the private setting in Basel as individual surgeons did not receive
a distinct code. Data from these registries could not be used for the
multivariate analysis and were analyzed separately.
statistical analysis
Socioeconomic and procedural covariates were compared with individual
scores. Pearson’s correlation was used to analyze the strength of the
relationship of items within the score, whereas the Student’s t-test and
analysis of variance were used to compare mean scores across different
groups. Bonferroni correction was applied when comparing multiple
groups.
Logistic regression analysis was carried out to find predictors for the
prospectively defined high (10 points) and low (£7 points) concordance in
univariate and multivariate analysis. In multivariate models, we included all
variables significantly linked to high or low scores in univariate analysis.
Because of the geographical disparities present, we tested the robustness of
our results by excluding one region at a time. Sensitivity analysis was
carried out to test assumptions of nondependence of results on any specific
region. All tests of significance were two sided; P < 0.05 was considered to
be significant. All statistical analyses were carried out using STATA 10.1
software (STATA Corp., College Station, TX).
results
Results of adherence to each of the items are detailed in Table 1.
Compliance with recommendations in surgical items was
poorer than in nonsurgical items. Among nonsurgical items,
noncompliance with recommendations of systemic therapies
was higher than for radiotherapy items.
Table 2 presents mean scores of state-of-the-art management
of breast cancer according to patient and tumor characteristics
as well as surgeon experience, multidisciplinary approaches
and involvement of the team in research. Mean total score was
8.64 [95% confidence interval (CI) 8.60–8.68, range 3–10]. A
total of 1147 patients (33%) had a score of 10 and 671 patients
(19%) a score of 7 or less. A high correlation was found
between the total score and the surgical subscore [coefficient
of regression (r) = 0.88, P < 0.001) as well as between the total
score and nonsurgical subscore (r = 0.57, P < 0.001), whereas
the correlation between surgical and nonsurgical subscores
was weak (r = 0.12, P < 0.01).
Most patients (95%) were treated within their canton of
residence and two-thirds in public hospitals.
Patients with tertiary education and living in an urban or
suburban area, and particularly in Geneva, had higher mean
and surgical scores. This was also observed for migrants
(Table 2).
One-third of patients were operated by surgeons with an
estimated caseload of six or less new breast cancer patients per
year. No significant differences in total or surgical subscores
were observed between patients operated by surgeons in the
intermediate (7–26 patients per surgeon and year) and low
tercile (£6 patients per surgeon per year) (8.67 and 3.84,
respectively, versus 8.54 and 3.84, P = 0.47). Both groups were
therefore considered together as low–intermediate group.
Patients treated by surgeons in the high-tercile category of
caseload (‡27 patients per surgeon per year) had a significantly
higher score (9.20 versus 8.54, P < 0.01) and surgical
subscore (4.37 versus 3.85, P < 0.01) than those treated by
surgeons in the low–intermediate group. Moreover, patients
treated by surgeons in the high-tercile group also had
significantly higher nonsurgical subscore than those treated
in the low–intermediate-tercile group (4.83 versus 4.73,
P < 0.01).
Discussion in an MDTC as defined previously was associated
with significantly higher mean total scores, higher surgical
subscore and higher nonsurgical subscore. The differences are
more clear-cut for patients discussed pre- and postoperatively.
In patients with missing information on caseload or MDTC,
all scores, total, surgical and nonsurgical, were significantly
lower (Table 2). Patients treated by physicians and institutions
participating in clinical research had a significantly higher total,
surgical and nonsurgical subscores (Table 2). When all three
characteristics were present (high caseload, MDTC and
participation in clinical research), the total score was 9.28
and the likelihood of a high score was three times higher
(odds ratio 3.06, 95% CI 2.56–3.66, P < 0.01). The setting
(public/private hospital) was not a predictor for high-score
category neither in univariate nor in multivariate analysis,
but setting was associated with a small but statistically
significant difference in score (Table 2). Missing information
on the type of setting was associated with low total (8.25, 95%
CI 8.14–8.36), surgical and nonsurgical scores.
Table 3 presents the effect of each factor on the probability of
having a high or low score of state-of-the-art treatment. In
univariate analysis, all patient characteristics studied were
significantly associated with both high and low score, except
stage, which was significantly linked to low management score
only. In multivariate analysis controlling for all other variables,
the effect of educational status, income category and MDTC
on high or low treatment score lost significance. Only place
of residence, surgeon caseload and research team experience
remained independently associated to a high score (Table 3).
In particular, surgeon caseload in the upper tercile and
participation in clinical research were associated with a 43%
and 42% increased chance to receive treatment according to
recommendations.
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Significant and independent association with low
management scores was observed for age, residence in
a rural area, canton of residence, and tumor and provider
characteristics (Table 3). In particular, older women aged
65–79 years have a 34% increased probability of having a low
treatment score compared with younger postmenopausal
Table 2. Patient and tumor characteristics and mean scores of state-of-the-art management of breast cancer according to patient, tumor and provider
characteristics
Characteristic No. of
patients (%)
Mean total score
(95% CI)
Mean surgical
score (95% CI)
Mean nonsurgical
score (95% CI)
All 3499 (100) 8.64 (8.60–8.68) 3.93 (3.89–3.96) 4.71 (4.69–4.73)
Age (years)
<35 71 (2) 8.79 (8.46–9.12) 4.03 (3.76–4.30) 4.76 (4.62–4.90)
35–49 787 (22) 8.64 (8.55–8.74) 3.86 (3.78–3.94) 4.78 (4.74–4.81)
50–65 1481 (42) 8.70 (8.64–8.77) 3.96 (3.90–4.01) 4.74 (4.71–4.77)
65–79 1160 (33) 8.55 (8.47–8.63) 3.92 (3.87–3.99) 4.62 (4.58–4.67)
Nationality
Swiss 2929 (84) 8.61 (8.56–8.66) 3.89 (3.85–3.93) 4.71 (4.69–4.74)
Foreigner 570 (16) 8.81 (8.71–8.91) 4.12 (4.03–4.20) 4.69 (4.64–4.75)
Residence
Urban/suburban 2791 (80) 8.72 (8.67–8.77) 4.00 (3.96–4.04) 4.72 (4.70–4.74)
Rural 708 (20) 8.32 (8.22–8.41) 3.63 (3.55–3.71) 4.68 (4.64–4.74)
Education
Tertiary 333 (10) 8.95 (8.82–9.08) 4.17 (4.06–4.27) 4.78 (4.71–4.84)
Other/unknown 3166 (90) 8.61 (8.56–8.66) 3.90 (3.86–3.94) 4.71 (4.68–4.73)
Income category
High 704 (20) 8.77 (8.67–8.87) 4.08 (4.00–4.16) 4.69 (4.64–4.74)
Others 2795 (80) 8.61 (8.56–8.66) 3.89 (3.85–3.94) 4.72 (4.69–4.74)
Canton of residence
GE 848 (24) 9.20 (9.12–9.27)a 4.38 (4.32–4.45)a 4.82 (4.79–4.86)
VS 446 (13) 8.46 (8.35–8.57) 3.60 (3.50–3.70) 4.87 (4.83–4.90)
TI 572 (16) 8.27 (8.15–8.38) 3.69 (3.60–3.79) 4.57 (4.52–4.63)
BA 356 (10) 8.47 (8.32–8.63) 3.84 (3.73–3.97) 4.63 (4.56–4.70)
ZH 379 (11) 8.62 (8.48–8.76) 4.06 (3.96–4.16) 4.56 (4.47–4.65)
SGA 608 (17) 8.62 (8.51–8.72) 3.81 (3.73–3.90) 4.79 (4.75–4.84)
GG 290 (0.8) 8.30 (8.15–8.46) 3.76 (3.62–3.86) 4.56 (4.48–4.65)
Stage
I 1564 (45) 8.57 (8.50–8.64) 3.85 (3.79–3.91) 4.72 (4.69–4.75)
II–III 1935 (55) 8.70 (8.64–8.76) 3.99 (3.95–4.04) 4.71 (4.68–4.74)
Receptors
ER and PR negative 561 (16) 8.54 (8.43–8.65) 3.87 (3.77–3.96) 4.68 (4.63–4.73)
ER or PR positive 2912 (84) 8.68 (8.63–8.73) 3.95 (3.91–3.99) 4.74 (4.72–4.76)
Histological grading
Low–intermediate 2621(76) 8.71 (8.67–8.76) 3.94 (3.90–3.98) 4.77 (4.75–4.80)
High 824 (24) 8.47 (8.38–8.57) 3.91 (3.84–3.99) 4.56 (4.52–4.61)
Surgical caseload
Low–intermediate 1791 (51) 8.54 (8.52–8.64)a 3.85 (3.80–3.90) 4.73 (4.70–4.76)
High 808 (23) 9.20 (9.13–9.27)a 4.37 (4.30–4.43) 4.83 (4.80–4.86)
Unknown 900 (26) 8.26 (8.16–8.35)a 3.68 (3.61–3.76) 4.56 (4.52–4.61)
MDTC, pre- and postoperative
No discussion 2194 (63) 8.64 (8.59–8.69)a 3.86 (3.81–3.91) 4.78 (4.75–4.80)
Yes 600 (17) 9.23 (9.15–9.31)a 4.40 (4.33–4.47)a 4.83 (4.79–4.86)a
Unknown 705 (20) 8.13 (8.03–8.23)a 3.73 (3.64–3.81) 4.40 (4.34–4.72)
Clinical research
No 1631 (46) 8.44 (8.37–8.51)a 3.79 (3.74–3.84) 4.65 (4.62–4.69)a
Yes 1279 (37) 9.07 (9.01–9.13)a 4.21 (4.15–4.26)a 4.87 (4.85–4.89)a
Unknown 589 (17) 8.24 (8.13–8.36)a 3.70 (3.61–3.79) 4.54 (4.49–4.60)a
Values in bold indicate statistically significant results.
aSignificantly different to all others with Bonferroni correction.
BA, Basel; CI, confidence interval; ER, estrogen receptor; GE, Geneva; GG, Grisons–Glarus; MDTC, multidisciplinary tumor conference; PR, progesterone
receptor; SGA, St Gallen–Appenzell; TI, Ticino; VS, Valais; ZH, Zurich.
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women. Surgeon caseload lower than the upper tercile and lack
of participation in clinical research were associated with
a 57% and 46% increased risk of having a low treatment score.
Because of geographical disparities present, we tested the
robustness of our results by excluding one region at a time.
Sensitivity analysis confirmed the robustness of the results.
discussion
This population-based study reports that provider
characteristics as well as area of residence are important and
independent predictors of adherence with recommendations
for management of early-stage breast cancer. In particular, high
Table 3. Relationship between patient, tumor and provider factors as predictors of high (10 points) and low (£7 points) scores
Characteristic High (10 point) management score Low (£7 point) management score
Univariate Multivariate Univariate Multivariate
Odds
ratio
95% CI Odds
ratio
95% CI Odds
ratio
95% CI Odds
ratio
95% CI
Age (years)
<35 1.31 0.80–2.14 1.22 0.66–2.25 0.82 0.42–1.58 0.90 0.38–2.12
35–49 0.92 0.76–1.10 0.82 0.65–1.04 1.01 0.81–1.26 1.20 0.89–1.64
50–65 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
65–79 0.83 0.70–0.98 0.82 0.67–1.01 1.29 1.06–1.56 1.34 1.03–1.75
Nationality
Swiss 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Foreign 1.38 1.15–1.66 1.06 0.83–1.35 0.71 0.56–0.91 0.86 0.67–1.34
Residence
Urban/suburban Ref Ref 1.0 Ref 1.0 Ref 1.0
Rural 0.42 0.36–0.52 0.68 0.51–0.90 1.55 1.27–1.89 1.39 1.03–1.87
Education
Tertiary 1.62 1.29–2.04 0.96 0.74–1.26 0.50 0.35–0.71 0.72 0.47–1.09
Other/unknown 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Income category
Upper quartile 1.40 1.17–1.67 0.93 0.74–1.18 0.82 0.66–1.01 0.98 0.69–1.38
Others 1.00 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Canton of residence
GE 5.25 3.79–7.28 2.92 1.97–4.33 0.28 0.20–0.40 0.57 0.36–0.90
VS 1.26 0.87–1.83 1.30 0.85–2.01 0.84 0.59–1.19 0.72 0.48–1.09
TI 1.16 0.81–1.67 – – 1.10 0.80–1.53 – –
BA 2.08 1.43–3.02 – – 0.99 0.69–1.42 – –
ZH 2.33 1.62–3.37 1.95 1.27–3.01 0.80 0.55–1.14 1.03 0.65–1.65
SGA 1.83 1.30–2.59 1.12 0.76–1.64 0.67 0.48–0.94 1.19 0.81–1.77
GG 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Stage
I 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
II–III 0.94 0.81–1.09 1.03 0.87–2.25 0.70 0.59–0.83 0.47 0.37–0.59
Receptors
ER and PR negative 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
ER or PR positive 1.17 0.96–1.43 1.12 0.84–1.49 0.78 0.63–0.98 0.89 0.63–1.25
Histological grading
Low–intermediate 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
High 0.72 0.62–0.87 0.83 0.65–1.07 1.36 1.13–1.65 1.45 1.08–1.95
Surgical caseload
Low–intermediate 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
High 2.57 2.16–3.04 1.43 1.07–1.91 0.32 0.24–0.43 0.43 0.27–0.67
MDTC, pre- and postoperative
No 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Yes 2.96 2.47–3.54 1.23 0.90–1.66 0.30 0.23–0.42 1.28 0.78–2.11
Clinical research
No 1.0 Ref 1.0 Ref 1.0 Ref 1.0 Ref
Yes 2.29 1.96–2.67 1.42 1.11–1.82 0.34 0.28–0.43 0.54 0.40–0.74
Values in bold indicate statistically significant odds ratios and 95% CI. Dash (–) indicates category dropped in the multivariate model because of missing data
for one of more covariates.
BA, Basel; CI, confidence interval; ER, estrogen receptor; GE, Geneva; GG, Grisons–Glarus; MDTC, multidisciplinary tumor conference; PR, progesterone
receptor; Ref, reference; SGA, St Gallen–Appenzell; TI, Ticino; VS, Valais; ZH, Zurich.
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surgeon experience in term of the number of breast cancer
patients treated (in this study >26 per year) and his or her team
involvement in clinical research are key determinants of use
of state-of-the-art management. Other factors such as patient’s
education, income and nationality, and MDTC are not
independent predictors of adequate management.
The influence of organizational factors on the process of care
and outcomes of breast cancer has been extensively investigated
in many countries. Hospital characteristics that have been
reported to positively affect treatments and outcomes include
teaching status [33–35], patient volume [34, 36–39], on-site
availability of specialized services needed for treatment [40–42],
discussion in multidisciplinary case conference [12] and
involvement in clinical research [43]. The results of our study are
in accordance with those reports. Patients treated in institutions
with high surgical caseload, with MDTC (especially when this
takes place before and after surgery) and with involvement in
clinical research resulted in an increased number of items
concordant with recommendations and guidelines. Especially,
surgical items as preoperative diagnosis and sentinel node biopsy
in patients with node-negative disease showed large variability.
The need for specialized breast units has been put forward by
the reports ‘A Policy Framework for Commissioning Cancer
Services’ [44] and ‘The Florence Statement’ [45], in 1995 and
1998, respectively. In 2000, EUSOMA published a list of
requirements of a specialist breast unit [46] including
multidisciplinary teams and members of the core team
spending at least half their working time in breast cancer. The
objectives of such units are to make a high-quality specialized
breast service available for all women, to define standards and
by means of accreditation to make this service recognizable to
patients, practitioners and health authorities as being of high
quality. Until the end of 2005, when the observation period of
this study ceased, only few specialized breast units were
available for patient care in Switzerland.
In Switzerland, 5200 patients are diagnosed with breast
cancer each year [47] and treated in nearly all 130 public and
private hospitals throughout the country. Because of this
fragmentation, only few centers reach the critical mass of more
than 150 newly diagnosed cases of primary cancer as required by
EUSOMA. The importance of specialization and multidisciplinary
approach is also reflected in our results. Patients treated by
surgeons in the upper tercile of caseload had not only higher
surgical scores but also better nonsurgical scores. Even if care by
general surgeons and gynecologists without specialization can be
excellent for common types of breast cancer, lack of specialization
can be critical in cases of nonpalpable mass, multicentricity or
special biological tumor and patient characteristics.
Among patient characteristics, older age, canton of residence
and living in a rural area were the only independent predictors of
low score, whereas tertiary education and income were not. Our
results are in accord with other studies showing that although
health disparities still exist in Switzerland, they are smaller than
the average among the European countries [48]. Geographical
disparities described in other studies [1–3] are confirmed in our
results and can be only imperfectly explained by the covariates
analyzed. Training policies and other decisions concerning hiring
and equipment taken many years ago may influence the quality
of care in the present study. More research is needed to fully
understand the causes of this variability. The high degree of
compliance with recommendations found in patients living in
the canton of Geneva is remarkable. A possible (but probably
incomplete) explanation is that in Geneva, most of the predictors
of high management score are present: high caseload and clinical
research at the university hospital, higher proportion of patients
with tertiary education, income in the highest tercile and living
in an urban area with high accessibility to specialized care. The
rather surprising finding that scores of nonnationals were higher
than those in nationals can be explained by the high proportion
of foreigners being treated by surgeons in the high tercile of
caseload (44% of foreigners versus 29% of nationals, P < 0.01).
Important strengths of this study are (i) that thanks to
identification of cases through cancer registries we have been able
to study patients in the community setting, in all type of
practices; (ii) that by using a tool developed to asses quality
we could assess a greater number of elements relevant for
practice; (iii) the fact that parameters, their exact definition and
categorization as well as the methodology of analysis had
been defined prospectively; (iv) the high degree of completeness
of data on adjuvant therapies and (v) that through the external
approach we were able to avoid biases related to self-selection and
self-reporting by caregivers. Moreover (vi), the time gap assured
a more complete registration of patients not treated in centers or
not treated at all, further reducing a possible selection bias [49].
Limitations of the study are related to the retrospective
perspective of data collection. Furthermore, almost half of the
population of Switzerland was not represented in the study
because of lack of population-based cancer registries in these
areas. However, the different linguistic regions of the country as
well as rural and urban populations are represented in this
study. Missing data on providers probably reduce the efficiency
of the analysis by enlarging CIs. We do not believe, however,
that it introduces any bias because it is concentrated on one
region (Ticino) and the private sector of the other (Basel).
Moreover, sensitivity analysis showed that the results are not
dependent on any specific region. As with most observational
studies, unobservable as well as unobserved differences between
those receiving standard, guideline congruent therapies and
those receiving nonstandard therapies are very likely to play
a role in the patterns of care we observed.
In the past few years, increasing awareness of variations in the
quality of health care across geographic areas as well as providers
has helped to propel a quality improvement movement. In
a system characterized by freedom of choice of provider, the
importance of an informed choice of referring physicians and
patients is paramount. The introduction of accredited breast
units in the near future will increase transparency, facilitate this
informed choice and contribute to reduce disparities.
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